Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.

Kowal, Krzysztof; Zukowski, S.; Moniuszko, Marcin; Bodzenta-Łukaszyk, Anna

doi:10.2478/v10042-008-0029-0

Cited by 20 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study supports previous observations linking the plasmin system with pathogenesis of allergic asthma [8][9][10][11][12][13][14][15][16]. In the present study we demonstrate that, in the airways of allergic asthma patients, allergen exposure leads to up-regulation of both components of the plasmin system: PAI-1 and uPA.…”

Section: Discussionsupporting

confidence: 93%

“…Sputum induction. Sputum was induced as described before [16]. Briefly, after premedication with 200 mcg of salbutamol patients inhaled hypertonic saline solution (3 to 5% NaCl).…”

Section: Methodsmentioning

confidence: 99%

“…Sputum PAI-1 and uPA concentrations were evaluated using enzyme-linked immunosorbent assays (Asserachrom, Diagnostica Stago, USA) according to the manufacturer's instruction as described before [16]. All samples were run in duplicates.…”

Section: Methodsmentioning

confidence: 99%

“…In humans, genetic variants of uPA and PAI-1 genes are associated with increased risk of allergic asthma [10][11][12][13][14][15]. In clinically stable, mild allergic asthma patients elevated levels of uPA and PAI-1 in induced sputum have recently been demonstrated [16]. Moreover, allergen exposure leads to elevation of plasma PAI-1 concentration in allergic asthma patients [17].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.

Kowal

Moniuszko²,

Zukowski³

et al. 2011

Folia Histochem Cytobiol.

Self Cite

View full text Add to dashboard Cite

Urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) are involved in tiisue remodeling and repair processes associated with acute and chronic inflammation. The aim of the study was to evaluate the effect of allergen challenge on concentration of uPA and PAI-1 in induced sputum of house dust mite allergic asthmatics (HDM-AAs). Thirty HDM-AAs and ten healthy persons (HCs)were recruited for the study. In 24 HDM-AAs bronchial challenge with Dermatophagoides pteronyssinus (Dp) and in 6 HDM-AAs sham challenege with saline were performed. In HDM-AAs sputum was induced 24 hours before (T 0 ) and 24 hours (T 24 ) after the challenge. Concentration of uPA and PAI-1 in induced sputum were determined using immunoenzymatic assays. At T 0 in HDM-AAs mean sputum uPA (151±96 pg/ml) and PAI-1 (4341±1262 pg/ml) concentrations were higher than in HC (18.8±6.7 pg/ml; p=0.0002 and 596±180 pg/ml; p<0.0001; for uPA and PAI-1 respectively). After allergen challenge further increase in sputum uPA (187±144 pg/ml; p=0.03) and PAI-1 (6252±2323 pg/ml; p<0.0001) concentrations were observed. Moreover, in Dp challenged, but not in saline challenged HDM-AAs the mean uPA/PAI-1 ratio decreased significantly at T 24 . No significant increase in the studied parameters were found in sham challenged patients. In HDM-AAs allergen exposure leads to activation of the plasmin system in the airways. Greater increase of the PAI-1 concentration than uPA concentration after allergen challenge may promote airway remodeling and play an important role in the development of bronchial hyperreactivity.

show abstract

Section: Discussionsupporting

confidence: 93%

“…Sputum induction. Sputum was induced as described before [16]. Briefly, after premedication with 200 mcg of salbutamol patients inhaled hypertonic saline solution (3 to 5% NaCl).…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.

Kowal

Moniuszko²,

Zukowski³

et al. 2011

Folia Histochem Cytobiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, recent studies showed that asthmatic subjects have increased concentrations of nonkinase plasminogen activator and plasminogen activator inhibitor [23] compared to controls and Neurokinin A significantly raises during exacerbations [24]. Interleukin-8 (IL-8) is a neutrophil chemoattractant which has been shown to be increased during asthma exacerbations [25] and in patients with severe persistent asthma [17], suggesting a role for monitoring asthma exacerbations and assessing the effectiveness of a medication in severe asthmatics.…”

Section: Fluid-phase Mediatorsmentioning

confidence: 99%

Markers of airway inflammation in pulmonary diseases assessed by induced sputum

Dragonieri

Tongoussouva

Zanini

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

During recent years there has been a growing interest in using non-invasive biomarkers to understand and monitor the airway inflammation in subjects with respiratory tract disorders. To date, the best validated and performing non-invasive biomarkers are measures of inflammation in induced sputum in both cellular and fluid phase, which can provide biological insights into the pathogenesis of respiratory diseases such as asthma and chronic obstructive pulmonary disease. The purpose of this review is to examine the principal literature on the different markers of inflammation in pulmonary diseases assessed by induced sputum analysis in either cellular or fluid phase.

show abstract

Identifying phenotypes and factors impacting outcomes in older adults with asthma: A research protocol and recruitment results

Polivka

Folz

Myers

et al. 2018

Research in Nursing & Health

View full text Add to dashboard Cite

Success in testing research outcomes requires identification of effective recruitment strategies in the targeted population. In this paper, we present the protocol for our NIH-funded study as well as success rates for the various recruitment strategies employed. This longitudinal observational study is: developing a phenotyping algorithm for asthma in older adults, exploring the effects of the asthma phenotype and of volatile organic compounds on asthma control, and developing a predictive model of asthma quality of life. A sub-aim is to characterize barriers to successful medication management in older adults with asthma. Individuals are eligible if they are ≥60 years, have a positive response to at least 1 of 6 asthma screening questions, non-smokers, and demonstrate bronchodilator reversibility or a positive bronchial challenge test with methacholine. Exclusion criteria are smokers who quit <5 years ago or with a >20 pack year smoking history, and those having other chronic pulmonary diseases. Participants (N=190) complete baseline pulmonary function testing, questionnaires, sputum induction, skin prick testing, and have blood drawn for Vitamin D and Immunoglobulin E. Home environmental assessments are completed including 24-hour particulate and volatile organic compound measurements. At 9-months post-baseline, home spirometry, medication assessment, and assessment of asthma quality of life and asthma control are assessed. At 18-months post-baseline, home spirometry, completion of baseline questionnaires, and a home environmental assessment are completed. We have employed multiple recruitment efforts including referrals from clinical offices, no-cost media events, flyers, and ads. The most successful efforts have been referrals from clinical offices and media events.

show abstract

Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.

Cited by 20 publications

References 21 publications

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.

Markers of airway inflammation in pulmonary diseases assessed by induced sputum

Identifying phenotypes and factors impacting outcomes in older adults with asthma: A research protocol and recruitment results

Contact Info

Product

Resources

About